[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639992":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":22,"responsibleParty":38,"collaborators":40,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":10,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Regina Elena Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with untreated non-small cell lung cancer",null,"Patients with untreated non-small cell lung cancer who will undergo curative surgery at the Thoracic Oncology Unit of the Regina Elena Cancer Institute in Rome were prospectively recruited.",[13],{"name":14,"affiliation":15,"role":16},"Paola Nisticò, Medical Doctor","IRCCS \"Regina Elena\" National Cancer Institude","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","+39 06 52662539","paola.nisticò@ifo.it",[23],{"facility":24,"status":25,"city":26,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"IRCCS National Cancer Institute \"Regina Elena\"","RECRUITING","Rome","00144","Italy","IT",{"type":31,"coordinates":32},"Point",[33,34],12.51133,41.89193,{"lat":34,"lon":33},[37],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},{"type":39,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[41],{"name":42,"class":6},"University of Catanzaro","100639992","standardization-of-a-platform-of-preclinical-models-derived-from-nsclc-patients-100639992",false,"NCT07629375","Standardization of a Platform of Preclinical Models Derived From NSCLC Patients","Standardization of a Platform of Preclinical Models Derived From NSCLC Patients to Investigate the Efficacy of New Nutraceutical Compounds Used as Monotherapy or in Combination With Immunotherapeutics or Chemo-immunotherapy","Inclusion criteria:\n\n* Patients over 18 years of age;\n* Patients diagnosed with resectable NSCLC who will undergo curative surgery;\n* Patients who give written informed consent (study participation and data processing).\n\nExclusion criteria:\n\n* Previous malignancies;\n* Previous systemic treatments.","ALL","18 Years",{"count":53,"type":54},5,"ESTIMATED","OBSERVATIONAL","Characterize and trace innovative nutraceuticals based on microencapsulated resveratrol and Cynara cardunculus extract, using preclinical models such as organotypic tissue slices and tumoroids created from tumor fragments derived from patients with non-small cell lung cancer. This will enable the development of combination therapies to increase the efficacy of immunotherapy in NSCLC and reduce side effects that lead to treatment discontinuation.\n\nThe market implementation of these products may offer unique advantages, including increased clinical efficacy, improved tolerability of immune checkpoint inhibitors, reduced healthcare costs, improved quality of life for patients and their families, traceability of naturally derived products, and environmental sustainability.",[58],"Non-Small Cell Lung Cancer","2026-06-04",{"date":61,"type":62},"2026-06-05","ACTUAL",{"date":64,"type":62},"2025-07-24",{"date":66,"type":54},"2026-07-24",{"name":5,"class":6},1]